Bioxcel Therapeutics (BTAI) Stock Statistics & Valuation Metrics

Bioxcel Therapeutics has a market cap or net worth of $34.89M. The enterprise value is $118.00M.

Bioxcel Therapeutics has 30,877,605 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bioxcel Therapeutics’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is -315.73%.

The current PE Ratio of Bioxcel Therapeutics is ―. Bioxcel Therapeutics’s PEG ratio is 0.00370.

In the last 12 months, Bioxcel Therapeutics had revenue of 642.00K and earned -69.90M in profits. Earnings per share was -5.73.

In the last 12 months, operating cash flow was -57.38M and capital expenditures 0.00, giving a free cash flow of -57.38M billion.

Bioxcel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Bioxcel Therapeutics upcoming earnings date is Aug 11, 2026, TBA (Confirmed).

Bioxcel Therapeutics as a current ratio of 0.83, with Debt / Equity ratio of -95.02%

In the past 12 months, Bioxcel Therapeutics has paid 0.00 in taxes.

Bioxcel Therapeutics EV to EBITDA ratio is -1.91, with an EV/FCF ratio of -1.75.

Bioxcel Therapeutics has $17.18M in cash and marketable securities with $100.29M in debt, giving a net cash position of -$83.11M billion.

Gross margin is 27.79%, with operating margin of -7829.75%, and net profit margin of -10887.38%.

The average price target for Bioxcel Therapeutics is $7.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy